Comparison of two gene transfer models for the attenuation of myocardial ischemia-reperfusion injury following preservation for cardiac transplantation
- PMID: 16487719
- DOI: 10.1016/j.ejcts.2005.12.051
Comparison of two gene transfer models for the attenuation of myocardial ischemia-reperfusion injury following preservation for cardiac transplantation
Abstract
Objective: Two models of ex vivo gene transfer were compared by examining the protective effect of adenovirus-mediated transfection of a free radical scavenger superoxide dismutase (SOD) during experimental ischemia-reperfusion mimicking preservation for cardiac transplantation.
Methods: Donor rat hearts (n=6 per group) were infused (subgroups IA and IB) or continually perfused (subgroups IIA and IIB) with solution containing adenoviral vector carrying beta-galactosidase (subgroups IA and IIA) or Mn-SOD (subgroups IB and IIB) over 5s with 1h storage and 15 min, at 4 degrees C, respectively. Hearts were then implanted heterotopically into the abdomen of recipient rats. Four days later, transplanted hearts were collected, connected to Langendorff perfusion apparatus and subjected to 6h of ischemia followed by 1h of reperfusion. Cardiac function was evaluated using intraventricular balloon at the beginning of Langendorff perfusion and following ischemia-reperfusion.
Results: Blue staining from hydrolyses of X-gal by beta-galactosidase was confirmed in AdLacZ transduced hearts. Immunoreactivity with anti-human Mn-SOD antibody then staining was positive in AdMnSOD-transduced hearts. Percent recovery of preischemic left ventricular developed pressure (LVDP) increased from 55.9+/-3.1% to 67.3+/-6.2% (P=0.048) and from 58.0+/-8.0% to 78.9+/-6.0% (P<0.001) in subgroups IA, IB, IIA and IIB, respectively. The difference in LVDP recovery between treatment groups of the two transfection methods (IB vs IIB) was significant (P=0.044).
Conclusion: Adenoviral Mn-SOD ex vivo delivery using continuous myocardial perfusion is superior to bolus infusion in the attenuation of myocardial ischemia-reperfusion injury.
Similar articles
-
Multigene adenoviral therapy for the attenuation of ischemia-reperfusion injury after preservation for cardiac transplantation.J Thorac Cardiovasc Surg. 2003 May;125(5):998-1006. doi: 10.1067/mtc.2003.263. J Thorac Cardiovasc Surg. 2003. PMID: 12771872
-
[Experimental studies of adenoviral-mediated exogenous gene transfer to donor heart].Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2007 Apr;21(4):416-9. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2007. PMID: 17546891 Chinese.
-
Intracoronary, adenovirus-mediated Akt gene transfer in heart limits infarct size following ischemia-reperfusion injury in vivo.J Mol Cell Cardiol. 2000 Dec;32(12):2397-402. doi: 10.1006/jmcc.2000.1283. J Mol Cell Cardiol. 2000. PMID: 11113015
-
Cardiac gene delivery using DNA-adenoviral constructs.Methods Mol Med. 2005;112:49-57. Methods Mol Med. 2005. PMID: 16010010 Review.
-
The vascular biology of heart and lung preservation for transplantation.Thromb Haemost. 1995 Jul;74(1):58-65. Thromb Haemost. 1995. PMID: 8578526 Review.
Cited by
-
Gene therapy during ex situ heart perfusion: a new frontier in cardiac regenerative medicine?Front Cardiovasc Med. 2023 Oct 16;10:1264449. doi: 10.3389/fcvm.2023.1264449. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37908499 Free PMC article. Review.
-
Recombinant adenoviral gene transfer does not affect cardiac allograft vasculopathy.J Heart Lung Transplant. 2007 Dec;26(12):1281-5. doi: 10.1016/j.healun.2007.09.018. J Heart Lung Transplant. 2007. PMID: 18096479 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical